ACHV
NASDAQ · Biotechnology
Achieve Life Sciences Inc
$7.75
+0.21 (+2.79%)
Financial Highlights (FY 2026)
Revenue
49.41B
Net Income
-122,414,034
Gross Margin
-98.8%
Profit Margin
-397.8%
Rev Growth
-44.7%
D/E Ratio
0.69
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -98.8% | -98.8% | 64.9% | 64.9% |
| Operating Margin | -418.8% | -376.9% | 2.0% | 1.9% |
| Profit Margin | -397.8% | -377.9% | 1.6% | 1.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 49.41B | 89.31B | 656.40M | 699.53M |
| Gross Profit | -48,802,095,606 | -88,201,871,689 | 425.96M | 453.94M |
| Operating Income | -206,934,523,868 | -336,600,526,804 | 13.43M | 13.07M |
| Net Income | -122,414,034 | -199,119,158 | 10.36M | 12.63M |
| Gross Margin | -98.8% | -98.8% | 64.9% | 64.9% |
| Operating Margin | -418.8% | -376.9% | 2.0% | 1.9% |
| Profit Margin | -397.8% | -377.9% | 1.6% | 1.8% |
| Rev Growth | -44.7% | -44.7% | +1.9% | +12.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 154.76M | 154.76M | 15.37M | 15.24M |
| Total Equity | 223.67M | 223.67M | 127.45M | 128.08M |
| D/E Ratio | 0.69 | 0.69 | 0.12 | 0.12 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -122,941,386 | -211,086,782 | 18.53M | 18.96M |
| Free Cash Flow | — | — | 6.70M | 12.14M |